ACSVL3 inhibitors are a class of chemical compounds or molecules designed to target and modulate the activity of the acyl-CoA synthetase very long-chain family member 3 (ACSVL3) protein. ACSVL3 is an enzyme that plays a vital role in cellular lipid metabolism, particularly in the activation of very long-chain fatty acids by conjugating them with coenzyme A (CoA), a crucial step in the biosynthesis of various lipid molecules. The inhibition of ACSVL3 is a focus of research aimed at elucidating its functions and roles in lipid homeostasis, lipid membrane composition, and other cellular processes where lipid metabolism is crucial. ACSVL3 inhibitors are developed using a variety of chemical synthesis and structural optimization methods, with the aim of specifically interacting with the ACSVL3 protein and modulating its enzymatic activity.
The design of ACSVL3 inhibitors typically involves creating molecules that can selectively bind to ACSVL3, thus disrupting its ability to catalyze the formation of acyl-CoA compounds. These inhibitors may target specific regions of the ACSVL3 protein, such as its active site or regulatory domains, to interfere with its enzymatic function. By modulating ACSVL3 activity, these inhibitors can provide valuable insights into the roles played by ACSVL3 in cellular lipid metabolism, membrane composition, and other cellular functions dependent on lipid biology. The study of ACSVL3 inhibitors contributes to our understanding of the complex mechanisms underlying lipid metabolism and its regulation within cells. This research helps researchers unravel the intricate molecular pathways involved in lipid biology, paving the way for further investigations into the broader implications of ACSVL3 in cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $51.00 | 7 | |
A lipase inhibitor, orlistat might influence lipid metabolism pathways, potentially affecting the expression of enzymes like ACSVL3. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $40.00 | 9 | |
As a PPARα agonist, fenofibrate affects lipid metabolism and could influence the expression of lipid-metabolizing enzymes. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $65.00 $262.00 | 2 | |
Another fibrate, gemfibrozil modulates lipid levels and might indirectly affect the expression of enzymes in lipid metabolism. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $142.00 | 8 | |
A statin that inhibits HMG-CoA reductase, rosiglitazone could indirectly influence lipid metabolism and ACSVL3 expression. | ||||||
Ezetimibe | 163222-33-1 | sc-205690 sc-205690A | 25 mg 100 mg | $94.00 $236.00 | 12 | |
By inhibiting cholesterol absorption, ezetimibe might impact lipid metabolism pathways, potentially affecting ACSVL3 expression. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
A PPARγ agonist, pioglitazone affects lipid and glucose metabolism, which might influence ACSVL3 expression. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $32.00 | ||
An older class of lipid-lowering agent, clofibrate affects lipid metabolism and could impact the expression of enzymes like ACSVL3. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
As a statin, lovastatin inhibits cholesterol synthesis, which might indirectly affect lipid metabolism and ACSVL3 expression. | ||||||
CHOLESTYRAMINE RESIN | 11041-12-6 | sc-507509 | 5 g | $210.00 | ||
A bile acid sequestrant, cholestyramine affects cholesterol metabolism, potentially impacting ACSVL3 expression. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Another statin, atorvastatin lowers cholesterol levels and might indirectly influence the expression of enzymes in lipid metabolism. | ||||||